Astrazeneca Pharma India receives Import and Market permission for Asthma drug

Image
Capital Market
Last Updated : Jun 15 2017 | 7:47 PM IST

From Drug Controller General of India

Astrazeneca Pharma India has received Import and Market permission in Form 45 (Marketing Authorization) from the Drug Controller General of India for FDC of Budesonide 320 g +Formoterol Fumarate Dihydrate 9 g inhalation powder.

FDC of Budesonide 320 g + Formoterol Fumarate Dihydrate 9 g inhalation powder (Symbicort Turbuhaler 320/9 g) is a product of AstraZeneca global and is indicated in the regular treatment of Asthma where use of combination of inhaled regular corticosteroid & long acting agonist is appropriate and patients with moderate to severe COPD with frequent symptoms and a history of exacerbations

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Jun 15 2017 | 7:17 PM IST

Next Story